2021-08-23| Special

New Era in Precision Medicine? Introduction & Overview of RNA Editing

by Kathy Huang
Share To
Compared to the well-known therapies centered around double-stranded DNA, the development of RNA therapeutics have advanced rather slowly. Scientists discovered the existence of messenger RNA (mRNA) in the 1960s, but the application of RNA editing began late in the 1990s. It was not until recently, the past two decades to be precise, that the development of RNA-related vaccines and the markets of new drug discovery began to flourish.

Although the techniques of DNA editing have been established longer, the major limitation lies in its irreversible characteristics; once DNA editing occurs, any unintended errors in the genome can’t be repaired easily. In contrast, RNA editing is reversible and produces fewer adverse reactions since RNAs are transient molecules. In this special series, we will focus on this potential gene-editing tool, introducing its history, clinical applications, industry trends, and interviews with experts in the field.

Discovery of RNA Editing in Living Organisms

The discovery of RNA editing can be traced back to 1986. Biologist Rob Benne and his group published a paper in the journal Cell focusing on the RNA editing mechanism in protozoa, marking the first discovery of RNA editing in living organisms. They observed that the transcript of the cytochrome oxidase coxII gene in the protozoan mitochondria has four inserted Uracil pairs not encoded by DNA. They named it “ RNA editing,” which refers to the phenomenon of post-transcriptional modifications on the RNA.

GO Prime with only $1.49 now

Should People Looking to Lose Weight Skip Sugar Substitutes?
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
A Close Look at the Evolution of ESG in Biopharma
Scientists Identified Potential New Drugs to Combat Blindness
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
The 2nd International Healthcare Week
Hong Kong , China
2023 ASCO annual meeting
Chicago, USA
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023 Bio Asia Pacific
Bangkok, Thailand
Scroll to Top